Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer

S.C. Glockner; M. Dhir; J.M. Yi; K.E. McGarvey; L. van Neste; J. Louwagie; T.A. Chan; W. Kleeberger; A.P. de Bruine; K.M. Smits; C.A. Khalid - de Bakker; D.M. Jonkers; R.W. Stockbrugger; G.A. Meijer; F.A. Oort; C. Iacobuzio Donahue; K. Bierau; J.G. Herman; S.B. Baylin; M. van Engeland; K E. Schuebel; N. Ahuja

doi:10.1158/0008-5472.CAN-08-0142

Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer

S.C. Glockner, M. Dhir, J.M. Yi, K.E. McGarvey, L. van Neste, J. Louwagie, T.A. Chan, W. Kleeberger, A.P. de Bruine, K.M. Smits, C.A. Khalid - de Bakker, D.M. Jonkers, R.W. Stockbrugger, G.A. Meijer, F.A. Oort, C. Iacobuzio Donahue, K. Bierau, J.G. Herman, S.B. Baylin, M. van EngelandK E. Schuebel, N. Ahuja^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

We have used a gene expression array-based strategy to identify the methylation of tissue factor pathway inhibitor 2 (TFPI2), a potential tumor suppressor gene, as a frequent event in human colorectal cancers (CRC). TFPI2 belongs to the recently described group of embryonic cell Polycomb group (PcG)-marked genes that may be predisposed to aberrant DNA methylation in early stages of colorectal carcinogenesis. Aberrant methylation of TFPI2 was detected in almost all CRC adenomas (97%, n = 56) and stages I to IV CRCs (99%, n = 115). We further explored the potential of TFPI2 as a biomarker for the early detection of CRC using stool DNA-based assays in patients with nonmetastatic CRC and average-risk noncancer controls who were candidates for screening. TFPI2 methylation was detected in stool DNA from stage I to III CRC patients with a sensitivity of 76% to 89% and a specificity of 79% to 93%. Detection of TFPI2 methylation in stool DNA may act as a useful adjunct to the noninvasive strategies for screening of CRCs in the future.

Original language	English
Pages (from-to)	4691-9
Journal	Cancer Research
Volume	69
Issue number	11
DOIs	https://doi.org/10.1158/0008-5472.CAN-08-0142
Publication status	Published - 1 Jan 2009

Access to Document

10.1158/0008-5472.CAN-08-0142

Cite this

Glockner, S. C., Dhir, M., Yi, J. M., McGarvey, K. E., van Neste, L., Louwagie, J., Chan, T. A., Kleeberger, W., de Bruine, A. P., Smits, K. M., Khalid - de Bakker, C. A., Jonkers, D. M., Stockbrugger, R. W., Meijer, G. A., Oort, F. A., Iacobuzio Donahue, C., Bierau, K., Herman, J. G., Baylin, S. B., ... Ahuja, N. (2009). Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Research, 69(11), 4691-9. https://doi.org/10.1158/0008-5472.CAN-08-0142

@article{135cfa1578144427910472509748f5f7,

title = "Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer",

abstract = "We have used a gene expression array-based strategy to identify the methylation of tissue factor pathway inhibitor 2 (TFPI2), a potential tumor suppressor gene, as a frequent event in human colorectal cancers (CRC). TFPI2 belongs to the recently described group of embryonic cell Polycomb group (PcG)-marked genes that may be predisposed to aberrant DNA methylation in early stages of colorectal carcinogenesis. Aberrant methylation of TFPI2 was detected in almost all CRC adenomas (97%, n = 56) and stages I to IV CRCs (99%, n = 115). We further explored the potential of TFPI2 as a biomarker for the early detection of CRC using stool DNA-based assays in patients with nonmetastatic CRC and average-risk noncancer controls who were candidates for screening. TFPI2 methylation was detected in stool DNA from stage I to III CRC patients with a sensitivity of 76% to 89% and a specificity of 79% to 93%. Detection of TFPI2 methylation in stool DNA may act as a useful adjunct to the noninvasive strategies for screening of CRCs in the future.",

author = "S.C. Glockner and M. Dhir and J.M. Yi and K.E. McGarvey and {van Neste}, L. and J. Louwagie and T.A. Chan and W. Kleeberger and {de Bruine}, A.P. and K.M. Smits and {Khalid - de Bakker}, C.A. and D.M. Jonkers and R.W. Stockbrugger and G.A. Meijer and F.A. Oort and {Iacobuzio Donahue}, C. and K. Bierau and J.G. Herman and S.B. Baylin and {van Engeland}, M. and Schuebel, {K E.} and N. Ahuja",

year = "2009",

month = jan,

day = "1",

doi = "10.1158/0008-5472.CAN-08-0142",

language = "English",

volume = "69",

pages = "4691--9",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "11",

}

Glockner, SC, Dhir, M, Yi, JM, McGarvey, KE, van Neste, L, Louwagie, J, Chan, TA, Kleeberger, W, de Bruine, AP , Smits, KM, Khalid - de Bakker, CA, Jonkers, DM, Stockbrugger, RW, Meijer, GA, Oort, FA, Iacobuzio Donahue, C, Bierau, K, Herman, JG, Baylin, SB, van Engeland, M, Schuebel, KE & Ahuja, N 2009, 'Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer', Cancer Research, vol. 69, no. 11, pp. 4691-9. https://doi.org/10.1158/0008-5472.CAN-08-0142

TY - JOUR

T1 - Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer

AU - Glockner, S.C.

AU - Dhir, M.

AU - Yi, J.M.

AU - McGarvey, K.E.

AU - van Neste, L.

AU - Louwagie, J.

AU - Chan, T.A.

AU - Kleeberger, W.

AU - de Bruine, A.P.

AU - Smits, K.M.

AU - Khalid - de Bakker, C.A.

AU - Jonkers, D.M.

AU - Stockbrugger, R.W.

AU - Meijer, G.A.

AU - Oort, F.A.

AU - Iacobuzio Donahue, C.

AU - Bierau, K.

AU - Herman, J.G.

AU - Baylin, S.B.

AU - van Engeland, M.

AU - Schuebel, K E.

AU - Ahuja, N.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - We have used a gene expression array-based strategy to identify the methylation of tissue factor pathway inhibitor 2 (TFPI2), a potential tumor suppressor gene, as a frequent event in human colorectal cancers (CRC). TFPI2 belongs to the recently described group of embryonic cell Polycomb group (PcG)-marked genes that may be predisposed to aberrant DNA methylation in early stages of colorectal carcinogenesis. Aberrant methylation of TFPI2 was detected in almost all CRC adenomas (97%, n = 56) and stages I to IV CRCs (99%, n = 115). We further explored the potential of TFPI2 as a biomarker for the early detection of CRC using stool DNA-based assays in patients with nonmetastatic CRC and average-risk noncancer controls who were candidates for screening. TFPI2 methylation was detected in stool DNA from stage I to III CRC patients with a sensitivity of 76% to 89% and a specificity of 79% to 93%. Detection of TFPI2 methylation in stool DNA may act as a useful adjunct to the noninvasive strategies for screening of CRCs in the future.

AB - We have used a gene expression array-based strategy to identify the methylation of tissue factor pathway inhibitor 2 (TFPI2), a potential tumor suppressor gene, as a frequent event in human colorectal cancers (CRC). TFPI2 belongs to the recently described group of embryonic cell Polycomb group (PcG)-marked genes that may be predisposed to aberrant DNA methylation in early stages of colorectal carcinogenesis. Aberrant methylation of TFPI2 was detected in almost all CRC adenomas (97%, n = 56) and stages I to IV CRCs (99%, n = 115). We further explored the potential of TFPI2 as a biomarker for the early detection of CRC using stool DNA-based assays in patients with nonmetastatic CRC and average-risk noncancer controls who were candidates for screening. TFPI2 methylation was detected in stool DNA from stage I to III CRC patients with a sensitivity of 76% to 89% and a specificity of 79% to 93%. Detection of TFPI2 methylation in stool DNA may act as a useful adjunct to the noninvasive strategies for screening of CRCs in the future.

U2 - 10.1158/0008-5472.CAN-08-0142

DO - 10.1158/0008-5472.CAN-08-0142

M3 - Article

C2 - 19435926

SN - 0008-5472

VL - 69

SP - 4691

EP - 4699

JO - Cancer Research

JF - Cancer Research

IS - 11

ER -